|
1
|
Harding T, Baughn L, Kumar S and Van Ness
B: The future of myeloma precision medicine: Integrating the
compendium of known drug resistance mechanisms with emerging tumor
profiling technologies. Leukemia. 33:863–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M,
Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma.
Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laubach J, Richardson P and Anderson K:
Multiple myeloma. Annu Rev Med. 62:249–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar
|
|
5
|
Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X,
Zhan X, Levasseur D, Zhou Y, Janz S, et al: ALDH1 activity
identifies tumor-initiating cells and links to chromosomal
instability signatures in multiple myeloma. Leukemia. 28:1155–1158.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fonseca R, Bergsagel PL, Drach J,
Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi
M, Minvielle S, et al: International myeloma working group
molecular classification of multiple myeloma: Spotlight review.
Leukemia. 23:2210–2221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Detappe A, Bustoros M, Mouhieddine TH and
Ghoroghchian PP: Advancements in nanomedicine for multiple myeloma.
Trends Mol Med. 24:560–574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mateos MV, Ludwig H, Bazarbachi A, Beksac
M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon
T, et al: Insights on multiple myeloma treatment strategies.
Hemasphere. 3:e1632018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guttman M, Amit I, Garber M, French C, Lin
MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al:
Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu N, Feng S, Li H, Chen X, Bai S and Liu
Y: Long non-coding RNA MALAT1 facilitates the tumorigenesis,
invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13
axis. J Cancer Res Clin Oncol. 146:367–379. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Wang H, Ruan J, Zheng W, Yang Z
and Pan W: Long non-coding RNA OIP5-AS1 suppresses multiple myeloma
progression by sponging miR-27a-3p to activate TSC1 expression.
Cancer Cell Int. 20:1552020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen Y, Feng Y, Chen H, Huang L, Wang F,
Bai J, Yang Y, Wang J, Zhao W, Jia Y, et al: Focusing on long
non-coding RNA dysregulation in newly diagnosed multiple myeloma.
Life Sci. 196:133–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu AX, Huang ZY, Zhang L and Shen J:
Potential prognostic long non-coding RNA identification and their
validation in predicting survival of patients with multiple
myeloma. Tumour Biol. 39:10104283176945632017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang H, Zhang C, Guan H, Liu J and Cui Y:
LncRNA DANCR promotes cervical cancer progression by upregulating
ROCK1 via sponging miR-335-5p. J Cell Physiol. 234:7266–7278. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan Z, Wu C, Li Y, Li H, An Y, Wang G, Dai
J and Wang Q: LncRNA DANCR silence inhibits SOX5-medicated
progression and autophagy in osteosarcoma via regulating
miR-216a-5p. Biomed Pharmacother. 122:1097072020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allegra A, Mania M, D'Ascola A, Oteri G,
Siniscalchi EN, Avenoso A, Innao V, Scuruchi M, Allegra AG,
Musolino C and Campo S: Altered long noncoding RNA expression
profile in multiple myeloma patients with bisphosphonate-induced
osteonecrosis of the Jaw. Biomed Res Int. 2020:98798762020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang G, Pian C, Chen Z, Zhang J, Xu M,
Zhang L and Chen Y: Identification of cancer-related miRNA-lncRNA
biomarkers using a basic miRNA-lncRNA network. PLoS One.
13:e01966812018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Handa H, Murakami Y, Ishihara R,
Kimura-Masuda K and Masuda Y: The role and function of microRNA in
the pathogenesis of multiple myeloma. Cancers (Basel). 11:17382019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu H, Wu Y, Wang S, Jiang J, Zhang C,
Jiang Y, Wang X, Hong L and Huang H: Circ-SMARCA5 suppresses
progression of multiple myeloma by targeting miR-767-5p. BMC
Cancer. 19:9372019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong Y, Hu L, Lu K, Wang Y, Xie Y, Gao L,
Yang G, Xie B, He W, Chen G, et al: Ferroportin downregulation
promotes cell proliferation by modulating the Nrf2-miR-17-5p axis
in multiple myeloma. Cell Death Dis. 10:6242019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F,
An G, Qin Y, Sui W, Li F, et al: Serum high expression of miR-214
and miR-135b as novel predictor for myeloma bone disease
development and prognosis. Oncotarget. 7:19589–19600. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu S, Cecilia Santini G, De Veirman K,
Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K and
Van Riet I: Upregulation of miR-135b is involved in the impaired
osteogenic differentiation of mesenchymal stem cells derived from
multiple myeloma patients. PLoS One. 8:e797522013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sweet DR, Fan L and Jain MK: Taking KLF9
to ‘Cort’ for crimes against metabolism. J Clin Invest.
129:2178–2180. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Imataka H, Sogawa K, Yasumoto K, Kikuchi
Y, Sasano K, Kobayashi A, Hayami M and Fujii-Kuriyama Y: Two
regulatory proteins that bind to the basic transcription element
(BTE), a GC box sequence in the promoter region of the rat P-4501A1
gene. EMBO J. 11:3663–3671. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhong Z, Zhou F, Wang D, Wu M, Zhou W, Zou
Y, Li J, Wu L and Yin X: Expression of KLF9 in pancreatic cancer
and its effects on the invasion, migration, apoptosis, cell cycle
distribution, and proliferation of pancreatic cancer cell lines.
Oncol Rep. 40:3852–3860. 2018.PubMed/NCBI
|
|
30
|
Kong YJ, Tan XX, Zhang Y, He QJ, Zhao L
and Meng Q: MiR-141 promotes cell proliferation and invasion in
non-small cell lung cancer by targeting KLF9. Eur Rev Med Pharmacol
Sci. 23:10370–10378. 2019.PubMed/NCBI
|
|
31
|
Mannava S, Zhuang D, Nair JR, Bansal R,
Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, et al:
KLF9 is a novel transcriptional regulator of bortezomib- and
LBH589-induced apoptosis in multiple myeloma cells. Blood.
119:1450–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
International Myeloma Working Group, :
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
international myeloma working group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Beule N, Menu E, Bertrand MJM, Favreau
M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez
S, et al: Experimental African trypanosome infection suppresses the
development of multiple myeloma in mice by inducing intrinsic
apoptosis of malignant plasma cells. Oncotarget. 8:52016–52025.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Z, Chen X, Xie R, Huang M, Dong W,
Han J, Zhang J, Zhou Q, Li H, Huang J and Lin T: DANCR promotes
metastasis and proliferation in bladder cancer cells by enhancing
IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 27:326–341.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai Y, Zhang G, Chu H, Li P and Li J: The
positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates
malignancy in non-small cell lung cancer. Am J Cancer Res.
9:270–284. 2019.PubMed/NCBI
|
|
38
|
Jia J, Li F, Tang XS, Xu S, Gao Y, Shi Q,
Guo W, Wang X, He D and Guo P: Long noncoding RNA DANCR promotes
invasion of prostate cancer through epigenetically silencing
expression of TIMP2/3. Oncotarget. 7:37868–37881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu QC, Rui ZH, Guo ZL, Xie W, Shan S and
Ren T: LncRNA-DANCR contributes to lung adenocarcinoma progression
by sponging miR-496 to modulate mTOR expression. J Cell Mol Med.
22:1527–1537. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Z, Gao Y, Gao S, Song D and Feng Y:
MiR-135b-5p promotes viability, proliferation, migration and
invasion of gastric cancer cells by targeting Krüppel-like factor 4
(KLF4). Arch Med Sci. 16:167–176. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao
L and Pei H: miR-135b-5p Promotes migration, invasion and EMT of
pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother.
96:1341–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen N, Yin D, Lun B and Guo X: LncRNA
GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through
the miR-135b-5p/CCND2 axis. Biosci Rep. 39:BSR201814402019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang
YR, Xu J, Wei W and Kang-Sheng G: Lnc SMAD5-AS1 as ceRNA inhibit
proliferation of diffuse large B cell lymphoma via Wnt/β-catenin
pathway by sponging miR-135b-5p to elevate expression of APC. Cell
Death Dis. 10:2522019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Zhang Z, Yi Y, Wang Y and Fu J:
CircNOL10 acts as a sponge of miR-135a/b-5p in suppressing
colorectal cancer progression via regulating KLF9. Onco Targets
Ther. 13:5165–5176. 2020. View Article : Google Scholar : PubMed/NCBI
|
